Systemic delivery of P42 peptide: a new weapon to fight Huntington's disease.

Abstract : Background:In Huntington’s disease (HD), the ratio between normal and mutant Huntingtin (polyQ-hHtt) iscrucial in the onset and progression of the disease. As a result, addition of normal Htt was shown to improvepolyQ-hHtt-induced defects. Therefore, we recently identified, within human Htt, a 23aa peptide (P42) thatprevents aggregation and polyQ-hHtt-induced phenotypes in HDDrosophilamodel. In this report, we evaluatedthe therapeutic potential of P42 in a mammalian model of the disease, R6/2 mice.Results:To this end, we developed an original strategy for P42 delivery, combining the properties of the cellpenetrating peptide TAT from HIV with a nanostructure-based drug delivery system (Aonys®technology), to form awater-in-oil microemulsion (referred to as NP42T) allowing non-invasiveper mucosalbuccal/rectal administration ofP42. Using MALDI Imaging Mass Spectrometry, we verified the correct targeting of NP42T into the brain, afterpermucosaladministration. We then evaluated the effects of NP42T in R6/2 mice. We found that P42 (and/or derivatives)are delivered into the brain and target most of the cells, including the neurons of the striatum. Buccal/rectal dailyadministrations of NP42T microemulsion allowed a clear improvement of behavioural HD-associated defects(foot-clasping, rotarod and body weights), and of several histological markers (aggregation, astrogliosis or ventricularareas) recorded on brain sections.Conclusions:These data demonstrate that NP42T presents an unprecedented protective effect, and highlight a newtherapeutic strategy for HD, associating an efficient peptide with a powerful delivery technology
Type de document :
Article dans une revue
Acta Neuropathologica Communications, BioMed Central part of Springer Science, 2013, pp.86
Liste complète des métadonnées

Littérature citée [51 références]  Voir  Masquer  Télécharger

http://www.hal.inserm.fr/inserm-01094108
Contributeur : Nadia Taibi <>
Soumis le : jeudi 11 décembre 2014 - 16:19:30
Dernière modification le : jeudi 11 janvier 2018 - 06:19:40
Document(s) archivé(s) le : samedi 15 avril 2017 - 07:54:41

Fichier

s40478-014-0086-x.pdf
Fichiers éditeurs autorisés sur une archive ouverte

Identifiants

  • HAL Id : inserm-01094108, version 1
  • PUBMED : 25091984

Citation

Yoan Arribat, Yasmina Talmat-Amar, Alexia Paucard, Pierre Lesport, Nathalie Bonneaud, et al.. Systemic delivery of P42 peptide: a new weapon to fight Huntington's disease.. Acta Neuropathologica Communications, BioMed Central part of Springer Science, 2013, pp.86. 〈inserm-01094108〉

Partager

Métriques

Consultations de la notice

119

Téléchargements de fichiers

129